Axsome Therapeutics (NASDAQ:AXSM) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Axsome Therapeutics (NASDAQ:AXSM) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. “

Other research analysts have also issued research reports about the company. Cantor Fitzgerald restated an overweight rating and issued a $35.00 price objective (up previously from $25.00) on shares of Axsome Therapeutics in a report on Tuesday, May 28th. ValuEngine lowered Axsome Therapeutics from a buy rating to a hold rating in a report on Thursday, August 1st. HC Wainwright set a $30.00 price objective on Axsome Therapeutics and gave the company a buy rating in a report on Monday, June 24th. SunTrust Banks initiated coverage on Axsome Therapeutics in a report on Tuesday, May 28th. They issued a buy rating on the stock. Finally, BidaskClub lowered Axsome Therapeutics from a buy rating to a hold rating in a report on Wednesday, June 12th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $30.83.

Shares of NASDAQ:AXSM opened at $25.23 on Tuesday. Axsome Therapeutics has a 1 year low of $1.94 and a 1 year high of $28.70. The firm has a market capitalization of $857.37 million, a price-to-earnings ratio of -21.94 and a beta of 2.64. The company has a debt-to-equity ratio of 0.72, a current ratio of 4.18 and a quick ratio of 4.18. The business’s 50 day moving average price is $25.83 and its 200-day moving average price is $18.87.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). On average, sell-side analysts expect that Axsome Therapeutics will post -1.49 earnings per share for the current year.

In other news, CFO Nick Pizzie acquired 1,920 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average price of $20.80 per share, for a total transaction of $39,936.00. Following the acquisition, the chief financial officer now owns 1,920 shares of the company’s stock, valued at approximately $39,936. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 27.50% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter worth $52,000. Focused Wealth Management Inc acquired a new stake in shares of Axsome Therapeutics in the 1st quarter worth $64,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter worth $72,000. Schroder Investment Management Group acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter worth $76,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Axsome Therapeutics in the 4th quarter worth $98,000. 50.85% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Further Reading: What is the 52-week high/low?

Get a free copy of the Zacks research report on Axsome Therapeutics (AXSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Armada Hoffler Properties  & Nam Tai Property  Head-To-Head Review
Armada Hoffler Properties & Nam Tai Property Head-To-Head Review
Critical Comparison: Taro Pharmaceutical Industries  and Genmab A/S
Critical Comparison: Taro Pharmaceutical Industries and Genmab A/S
Critical Comparison: Jerash Holdings   versus Its Rivals
Critical Comparison: Jerash Holdings versus Its Rivals
Comparing Symantec  & Tyler Technologies
Comparing Symantec & Tyler Technologies
LegacyTexas Financial Group  Raised to Buy at BidaskClub
LegacyTexas Financial Group Raised to Buy at BidaskClub
Adverum Biotechnologies  PT Lowered to $8.00 at SunTrust Banks
Adverum Biotechnologies PT Lowered to $8.00 at SunTrust Banks


 
© 2006-2019 Zolmax.